Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
SA SAGE Sage Therapeutics, Inc. FY ended Feb 04, 2025 | — | — | — | $41.24M | -$399.64M | -$400.67M | — | — | — |
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
AL ALKS Alkermes plc. FY ended Feb 20, 2026 | $47.41 | $7.95B | $7.57B | $1.48B | $346.68M | $241.66M | 33.15x | 5.39x | 20.47x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
KR KRYS Krystal Biotech, Inc. FY ended Feb 11, 2026 | $351.46 | $10.40B | $9.99B | $389.13M | $196.69M | $204.83M | 51.38x | 26.73x | 50.56x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 32.61x | 5/6 | $4.83B | $28.06 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 8.40x | 5/6 | $9.00B | $52.25 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -1.44x | 5/6 | -$561.21M | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
SA SAGE Sage Therapeutics, Inc. FY ended Feb 04, 2025 | — | — | — | $41.24M | -$399.64M | -$400.67M | — | — | — |
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
AL ALKS Alkermes plc. FY ended Feb 20, 2026 | $47.41 | $7.95B | $7.57B | $1.48B | $346.68M | $241.66M | 33.15x | 5.39x | 20.47x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
KR KRYS Krystal Biotech, Inc. FY ended Feb 11, 2026 | $351.46 | $10.40B | $9.99B | $389.13M | $196.69M | $204.83M | 51.38x | 26.73x | 50.56x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 32.61x | 5/6 | $4.83B | $28.06 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 8.40x | 5/6 | $9.00B | $52.25 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -1.44x | 5/6 | -$561.21M | — | Peer averages are not economically meaningful for this method. |
